SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

Stopped Decision to terminate EZH-1401 was solely due to company business decision.

Conditions

• Follicular Lymphoma

Interventions

• DRUG: Tazemetostat
• COMBINATION_PRODUCT: Rituximab

Sponsor

Epizyme, Inc.

Collaborators

• [object Object]